Lyme Disease Halifax

Lyme Disease – Information on Lyme Disease- Life stories of Lyme disease

Browsing Posts tagged idsa treatment guidelines

Dr. Phil after the “Deadly Consequence’s” show stated he should have touched more on the “Key Elements” regarding the Conflicts of Interest pertaining to Lyme.
That comment was HUGE !!
Thankyou again !!

See link here:

http://www.drphil.com/uncut/page/uncensored/

When serum samples were tested for anti-Borrelia antibodies using eight commercially available ELISAs and five immunoblot assays, intertest agreement was only modest.

Current guidelines for diagnosing Lyme disease include a two-tier testing algorithm: an enzyme-linked immunosorbent assay (ELISA) for detecting anti-Borrelia antibodies, followed by immunoblot confirmation of positive ELISA results. Commercially available tests are based on sonicated whole-cell Borrelia antigens, recombinant antigens, or a mixture of the two.
To compare the performance of these assays, researchers in the Netherlands tested serum samples for anti-Borrelia antibodies using eight commercial ELISAs and five immunoblots (4 commercial, 1 investigator-made). The 89 samples were from 59 patients with suspected Lyme disease, 14 healthy controls, and 16 patients with syphilis or Mycoplasma pneumoniae infection — conditions associated with highly cross-reactive antibodies.
Of the 89 samples, 35 (39%) tested negative — and 16 (18%) tested positive — on all ELISAs. The remaining 38 (43%) tested positive on one to seven ELISAs. The proportion of samples with positive results on any one ELISA ranged from 34% to 59% for patients with suspected Lyme disease and from 0% to 38% for patients with cross-reactive antibodies. Samples from healthy controls almost always had negative ELISA results.
Thirty-one of the samples from patients with suspected Lyme disease were also tested with all immunoblots. Interblot agreement was low (IgG, 30%–84%; IgM, 0%–46%), and it was no higher for recombinant antigens than for whole-cell antigens. Some samples that tested negative on all ELISAs showed blot reactivity; some that tested positive on all ELISAs tested negative on all blots.
Comment: These findings are sobering and, unfortunately, do not facilitate diagnosis of Lyme disease. Clinicians should rely on a precise clinical determination of Lyme disease, interpreting serologic test results with great caution. Clearly, several possible ELISA/blot combinations do not work together very well. Furthermore, there are true Lyme cases with positive ELISA but negative blot results (depending on the test used), and even a few with negative ELISA but positive blot results.
— Thomas Glück, MD

Published in Journal Watch Infectious Diseases August 31, 2011

http://infectious-diseases.jwatch.org/cgi/content/full/2011/831/1

Will update post soon with details how you can help.

 

There is a lot to like about the Virginia Governor’s Task Force on Lyme Disease findings, which were unanimously adopted on June 30th after a number of public hearings. The report totals 19 pages and it is remarkably balanced. Congratulations to all involved! I want to share with you what I like about the report by highlighting key points from the findings on Diagnosis, Treatment, Public Education and Prevention, and Children.

I have excerpted the most important components of the report in my opinion and have left the section titles and paragraph numbers intact for those wanting to follow along with the full report, which you can download at the bottom of this post.

[W]e make the following specific findings and recommendations based on the testimony that we received from our hearings:

See more here:

http://www.lymedisease.org/news/lymepolicywonk/766.html